Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $2.7 million.

  • Lyell Immunopharma's Other Non-Current Liabilities fell 24.80% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 24.80%. This contributed to the annual value of $3.3 million for FY2024, which is 11.22% down from last year.
  • Per Lyell Immunopharma's latest filing, its Other Non-Current Liabilities stood at $2.7 million for Q3 2025, which was down 11.52% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Non-Current Liabilities ranged from a high of $5.0 million in Q3 2021 and a low of $900,000 during Q2 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $3.6 million (2024), whereas its average is $3.5 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Other Non-Current Liabilities spiked by 758.27% in 2021, and later decreased by 24.80% in 2025.
  • Lyell Immunopharma's Other Non-Current Liabilities (Quarterly) stood at $4.6 million in 2021, then decreased by 9.92% to $4.1 million in 2022, then declined by 10.92% to $3.7 million in 2023, then dropped by 11.22% to $3.3 million in 2024, then fell by 24.80% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $3.0 million for Q2 2025, and $3.1 million during Q1 2025.